4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Common Equity of $451.8 million for Q1 2026, down 3.81% year-over-year from $469.7 million in Q1 2025, and down 10.65% quarter-over-quarter from $505.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Common Equity for 8 consecutive years, with $451.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 3.81% year-over-year to $451.8 million; the TTM figure through Mar 2026 stood at $451.8 million (down 3.81% YoY), while the FY2025 annual figure was $505.7 million, down 0.97% from the prior year.
- Common Equity declined to $451.8 million in Q1 2026 per FDMT's latest filing, from $505.7 million in the prior quarter.
- Across five years, Common Equity topped out at $600.6 million in Q1 2024 and bottomed at $218.6 million in Q1 2023.
- Historically, Common Equity has averaged $394.3 million across 5 years, with a median of $369.0 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity soared 174.72% — and 2025, when it slumped 33.27%.
- 4D Molecular Therapeutics' Common Equity stood at $231.3 million in 2022, then soared by 33.07% to $307.8 million in 2023, then jumped by 65.87% to $510.6 million in 2024, then declined by 0.97% to $505.7 million in 2025, then decreased by 10.65% to $451.8 million in 2026.
- Business Quant data shows FDMT's Common Equity at $451.8 million in Q1 2026, $505.7 million in Q4 2025, and $369.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 407.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.66 Mn |
| Mar 31, 2026 | 451.84 Mn |
| Dec 31, 2025 | 505.66 Mn |
| Sep 30, 2025 | 368.98 Mn |
| Jun 30, 2025 | 420.89 Mn |
| Mar 31, 2025 | 469.72 Mn |
| Dec 31, 2024 | 510.61 Mn |
| Sep 30, 2024 | 552.95 Mn |
| Jun 30, 2024 | 588.34 Mn |
| Mar 31, 2024 | 600.56 Mn |
| Dec 31, 2023 | 307.83 Mn |
| Sep 30, 2023 | 329.93 Mn |
| Jun 30, 2023 | 325.14 Mn |
| Mar 31, 2023 | 218.61 Mn |
| Dec 31, 2022 | 231.34 Mn |
| Sep 30, 2022 | 251.44 Mn |
| Jun 30, 2022 | 272.52 Mn |
| Mar 31, 2022 | 296.06 Mn |
| Dec 31, 2021 | 319.11 Mn |
| Sep 30, 2021 | 224.13 Mn |